<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01292447</url>
  </required_header>
  <id_info>
    <org_study_id>10-0084</org_study_id>
    <nct_id>NCT01292447</nct_id>
  </id_info>
  <brief_title>A Trial of 2% Lidocaine Gel for Intrauterine Device (IUD) Insertion</brief_title>
  <official_title>A Randomized Controlled Trial of 2% Lidocaine Gel for IUD Insertion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Women and Infants Hospital of Rhode Island</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Women and Infants Hospital of Rhode Island</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The intrauterine device (IUD) is a long-acting, highly effective, reversible contraceptive&#xD;
      that may be underutilized due to fear of pain during insertion. Although providers frequently&#xD;
      prescribe non-steroidal anti-inflammatory drugs (NSAIDs) for IUD insertion, there is no&#xD;
      evidence for any pain reduction. In fact, no interventions evaluated in randomized controlled&#xD;
      trials have been shown to be effective in reducing pain during IUD insertion. While many&#xD;
      women tolerate IUD insertion well, others have moderate to severe pain. This double-blind&#xD;
      randomized controlled trial of 150 women aims to estimate the efficacy of intracervical 2%&#xD;
      lidocaine gel compared to placebo (KY jelly) to reduce IUD insertion pain. Our hypothesis is&#xD;
      that women who are treated with 2% lidocaine gel prior to IUD insertion will have reduced&#xD;
      pain as measured on a 0 mm to 100 mm Visual Analog Scale (VAS). We will be able to detect a&#xD;
      15 mm difference on the VAS with our sample size. Other data to be collected include&#xD;
      information regarding age, BMI, obstetric history, lactation status, time since pregnancy or&#xD;
      delivery, last menstrual period, history of cervical conization, anxiety levels, anticipated&#xD;
      pain levels, insertion characteristics (time, difficulty, complications), side effects, and&#xD;
      satisfaction with pain control. If 2% lidocaine gel is effective, then a viable, easily&#xD;
      administered option for pain control will be available to providers and patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Pain Score During IUD Insertion</measure>
    <time_frame>Day 1</time_frame>
    <description>0 to 100 mm visual analog scale, higher values represent more pain.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Will receive placement of inert glycerin gel on ectocervix and in cervical canal prior to IUD placement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will receive placement of 2% lidocaine gel on ectocervix and in cervical canal prior to IUD placement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2% lidocaine gel</intervention_name>
    <description>120mg lidocaine x 1</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo gel</intervention_name>
    <description>Inert gel x 1</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. plans for IUD insertion for contraception or abnormal uterine bleeding;&#xD;
&#xD;
          2. 18 to 49 years of age;&#xD;
&#xD;
          3. reached more than 6 weeks postpartum or 2 weeks postabortion if recently pregnant;&#xD;
&#xD;
          4. no prior IUD use;&#xD;
&#xD;
          5. not taken analgesics or anxiolytics in the previous 24 hours;&#xD;
&#xD;
          6. not taken misoprostol prior to IUD insertion;&#xD;
&#xD;
          7. the ability and are willing to give informed consent;&#xD;
&#xD;
          8. speaks English or Spanish.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. any contraindication to IUD placement;&#xD;
&#xD;
          2. allergy to lidocaine or sensitivities to components of the lidocaine or placebo gel;&#xD;
&#xD;
          3. chronic narcotic/benzodiazepine/barbiturate use within the past year.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca H Allen, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Women and Infants Hospital of Rhode Island</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Women's Primary Care Center/Women and Infants' Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Womens Primary Care Center</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 24, 2011</study_first_submitted>
  <study_first_submitted_qc>February 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2011</study_first_posted>
  <results_first_submitted>August 14, 2020</results_first_submitted>
  <results_first_submitted_qc>August 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 2, 2020</results_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Women and Infants Hospital of Rhode Island</investigator_affiliation>
    <investigator_full_name>Rebecca H. Allen, MD</investigator_full_name>
    <investigator_title>Assistant Professor ob/gyn</investigator_title>
  </responsible_party>
  <keyword>Pain measurement</keyword>
  <keyword>Intrauterine devices</keyword>
  <keyword>Lidocaine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control Group</title>
          <description>Will receive placement of inert glycerin gel on ectocervix and in cervical canal prior to IUD placement.&#xD;
Placebo gel: Inert gel x 1</description>
        </group>
        <group group_id="P2">
          <title>Study Group</title>
          <description>Will receive placement of 2% lidocaine gel on ectocervix and in cervical canal prior to IUD placement.&#xD;
2% lidocaine gel: 120mg lidocaine x 1</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control Group</title>
          <description>Will receive placement of inert glycerin gel on ectocervix and in cervical canal prior to IUD placement.&#xD;
Placebo gel: Inert gel x 1</description>
        </group>
        <group group_id="B2">
          <title>Study Group</title>
          <description>Will receive placement of 2% lidocaine gel on ectocervix and in cervical canal prior to IUD placement.&#xD;
2% lidocaine gel: 120mg lidocaine x 1</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="73"/>
            <count group_id="B2" value="72"/>
            <count group_id="B3" value="145"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.2" spread="5"/>
                    <measurement group_id="B2" value="26.2" spread="5.3"/>
                    <measurement group_id="B3" value="25.7" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Pain Score During IUD Insertion</title>
        <description>0 to 100 mm visual analog scale, higher values represent more pain.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Will receive placement of inert glycerin gel on ectocervix and in cervical canal prior to IUD placement.&#xD;
Placebo gel: Inert gel x 1</description>
          </group>
          <group group_id="O2">
            <title>Study Group</title>
            <description>Will receive placement of 2% lidocaine gel on ectocervix and in cervical canal prior to IUD placement.&#xD;
2% lidocaine gel: 120mg lidocaine x 1</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Score During IUD Insertion</title>
          <description>0 to 100 mm visual analog scale, higher values represent more pain.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7" spread="30"/>
                    <measurement group_id="O2" value="35.2" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Control Group</title>
          <description>Will receive placement of inert glycerin gel on ectocervix and in cervical canal prior to IUD placement.&#xD;
Placebo gel: Inert gel x 1</description>
        </group>
        <group group_id="E2">
          <title>Study Group</title>
          <description>Will receive placement of 2% lidocaine gel on ectocervix and in cervical canal prior to IUD placement.&#xD;
2% lidocaine gel: 120mg lidocaine x 1</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Acute complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rebecca Allen</name_or_title>
      <organization>Women and Infants Hospital</organization>
      <phone>4012741122</phone>
      <email>rhallen@wihri.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

